Balloon Valvuloplasty Device Market Report 2024

The balloon valvuloplasty device market size has grown strongly in recent years. It will grow from $2.31 billion in 2023 to $2.44 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historical period can be attributed to rising healthcare expenditure, expansion of healthcare infrastructure, improved awareness and diagnostic capabilities, a shift towards outpatient settings, the advancement of telemedicine enhancing access to care, and a focus on enhancing the quality of life for patients.

The balloon valvuloplasty device market size is expected to see strong growth in the next few years. It will grow to $3.06 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to the rising prevalence of heart valve diseases among elderly populations globally, greater adoption of minimally invasive treatments for heart valve conditions, expedited approvals and clearances for new balloon valvuloplasty devices, and a focus on cost-effective healthcare solutions. Major trends anticipated in this period include advancements in imaging technologies facilitating precise diagnosis, the adoption of personalized medicine approaches, increased investments in research and development, expansion of regenerative techniques in managing cardiovascular diseases, and integration of digital health technologies into cardiovascular care.

The balloon valvuloplasty device market is poised for growth driven by increasing preference for minimally invasive procedures. Minimally invasive techniques involve performing medical procedures through small incisions or natural body openings, resulting in quicker recovery times, reduced risk of complications, and less post-operative discomfort compared to traditional surgeries. Balloon valvuloplasty devices are integral to these procedures, used to widen narrowed heart valves, enhance blood flow, and alleviate symptoms. For example, Intuitive Surgical Inc., a US-based leader in robotic surgical systems, reported a 12% increase in placements of their da Vinci surgical systems in the fourth quarter of 2023, underscoring the rising adoption of minimally invasive approaches driving the balloon valvuloplasty device market.

Key players in the balloon valvuloplasty device market are innovating with advanced products such as Pacing Guidewires to maintain competitiveness. Pacing guidewires are specialized tools used during procedures to provide temporary cardiac pacing, ensuring heart stability while balloon catheters dilate narrowed valves. For instance, Teleflex Incorporated, a US-based medical device company, recently received FDA clearance for the Wattson Temporary Pacing Guidewire in June 2023. This device is tailored for use in transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV) procedures, featuring a flexible distal pigtail shape, multiple electrodes, and bipolar design to enhance safety and efficacy. It supports valve delivery and ventricular pacing, reducing the risk of complications such as ventricular perforation and ensuring reliable electrical capture during rapid pacing.

In November 2023, OrbusNeich Medical Group Holdings Limited, headquartered in Hong Kong, acquired Eucatech AG for $2.3 million. This strategic acquisition enhances OrbusNeich's capabilities in providing comprehensive treatment solutions for cardiovascular diseases, bolstering its balloon valvuloplasty device offerings. Eucatech AG, based in Germany, is renowned for its innovative medical technology solutions including balloon valvuloplasty devices.

Major companies operating in the balloon valvuloplasty device market are Cardinal Health Inc., Abbott Laboratories, Medtronic plc, Philips Healthcare, Becton Dickinson Company, Boston Scientific Corporation, B. Braun Melsungen AG, Terumo Corporation, Teleflex Incorporated, Biotronik SE & Co. KG, Integer Holdings Corporation, LivaNova PLC, Cordis Corporation, NuMED Inc., Pfm Medical GmbH, Tokai Medical Products Inc, Translumina GmbH, Meril Life Sciences Pvt. Ltd., Toray Medical Company Limited, QT Vascular Ltd.

North America was the largest region in the balloon valvuloplasty device market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the balloon valvuloplasty device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the balloon valvuloplasty device market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A balloon valvuloplasty device is a medical instrument used in the treatment of heart valve stenosis. This procedure involves inserting a balloon into the narrowed valve and inflating it to widen the opening, thereby improving blood flow. It is a minimally invasive approach aimed at relieving symptoms such as chest pain and shortness of breath, ultimately enhancing cardiac function and improving patient quality of life.

The primary types of balloon valvuloplasty devices include standard balloons, cutting balloons, scoring balloons, high-pressure balloons, and low-pressure balloons. Standard balloon valvuloplasty devices are specifically designed to treat narrowed heart valves by expanding the valve opening through balloon inflation. This procedure is commonly performed in minimally invasive settings to alleviate symptoms associated with valve narrowing. These devices are used across pediatric and adult populations and are employed in various healthcare settings including hospitals, ambulatory surgical centers, specialty clinics, and others.

The balloon valvuloplasty device market research report is one of a series of new reports that provides balloon valvuloplasty device market statistics, including balloon valvuloplasty device industry global market size, regional shares, competitors with a balloon valvuloplasty device market share, detailed balloon valvuloplasty device market segments, market trends and opportunities, and any further data you may need to thrive in the balloon valvuloplasty device industry. This balloon valvuloplasty device market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The balloon valvuloplasty device market consists of sales of scoring balloons, high-pressure balloons, and standard balloons. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.